MARKET WIREYahoo! Finance Canada • 14h ago
Immatics N.V. (IMTX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
Why IMTX Stock slipped -1.50% Today — RQD Quant Desk Flash
$7.20 -1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.17
Immatics N.V. (IMTX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.09B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.20 (-1.50% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMTX ranks #402 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMTX compare to INBX and CGEM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMTX?
▼
For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #402 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.17 (-0.46%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMTX)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY IMTX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)
SEC XBRL Trailing 12 Months: 0.8% FCF Margin ($30.6M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$7.21-2.2% Next Q
53
Q2 (-2Q)Grade C-$7.05+1.4% Next Q
50
Q3 (-1Q)Grade D$7.15+0.7% Next Q
48
CurrentGrade D$7.20-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMTX Turnaround Squeeze
While IMTX currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.22) and Max Pain ($7.56) forces dealer call-delta covering toward $13.03.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMTX Stock slipped -1.50% Today — RQD Quant Desk Flash
Immatics N.V. (IMTX) slipped -1.50% to $7.20, trading at 10% of its 52-week range ($6.65 – $12.41). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 10% of its 52-week range ($6.65 – $12.41) with RSI-14 at 44.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $7.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $30.6M annual free cash flow.
Live IMTX Headlines & Catalysts
MARKET WIREYahoo Finance UK • 17h ago
Immatics N.V. (IMTX) stock price, news, quote and historyYahoo Finance UK report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 20h ago
Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to BrokeragesMarketBeat report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Traders Daily • 1d ago
Precision Trading with Immatics N.v. (IMTX) Risk ZonesStock Traders Daily report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
One-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients.Stock Titan report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine Media • 1d ago
Can Immatics N.V. (NASDAQ:IMTX) Overcome Its Latest Financial Setback?Kalkine Media report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Immatics (NASDAQ:IMTX) Hits New 1-Year Low - Here's What HappenedMarketBeat report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 2d ago
Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In FocusWhat the new PRAME data means for Immatics stock Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at t
CATALYSTYahoo • 4d ago
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesBristol Myers (BMY) delivered earnings and revenue surprises of +11.57% and +4.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
CATALYSTYahoo • 5d ago
Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data ImpressesImmatics has logged a sizeable share price decline over the past few years, even as fresh clinical data has put its PRAME cancer therapies in the spotlight. That raises a straightforward question for you as an investor:
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMTX)
- ✓Walkthrough of IMTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.37%▼ DESCENDING CHANNEL
2026-11-02O $7.35H $7.35L $7.20C $7.20VOL 1.18M
RES: $8.46SUP: $6.17SMA50: $8.22SMA200: $9.58
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMTX)
Health Care Rank #402 of 1016
⚔️ INBX vs IMTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMTX vs. INBX, CGEM, VOR, ODTX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Immatics N.V. (IMTX) ranks #402 by composite RQD confidence (45/100, grade D) and #352 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IMTX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with IMTX at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMTX
ACTIVE
Immatics N.V. | D | 45/100 | — | — | — | -1.50% | $1.09B | Benchmark Subject |
| INBX Inhibrx Biosciences Inc. | E | 18/100 | — | — | -35.0% | -2.54% | $1.08B | /inbx-vs-imtx → |
| CGEM Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -2.72% | $994.3M | /cgem-vs-imtx → |
| VOR Vor Biopharma Inc. | D | 46/100 | — | — | -35.0% | -5.88% | $1.24B | /vor-vs-imtx → |
| ODTX Odyssey Therapeutics Inc. | D+ | 52/100 | — | — | — | -1.46% | $953.0M | /odtx-vs-imtx → |
2. IMTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTImmatics N.V. (IMTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.09B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. IMTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.20 (-1.50% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMTX ranks #402 in composite RQD confidence.
How does IMTX compare to INBX and CGEM in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMTX?
For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #402 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMTX trading relative to its 50-day, 200-day, and 52-week technical levels?
IMTX last traded at $7.20 (-1.50% on volume of 1,715,922 shares), positioning the stock -12.41% below its 50-day simple moving average ($8.22) and -24.84% below its 200-day simple moving average ($9.58). Across its 52-week range of $6.65 to $12.41, IMTX sits at the 9.5% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($6.34 to $8.06).
IMTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMTX stock moving today?
Why IMTX Stock slipped -1.50% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 45/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IMTX — Immatics N.V.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:05Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IMTX scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:
- Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash yield to anchor valuation.
- Whale 13F Flow: 3 / 20. This pillar, covering institutional accumulation and options positioning, is the weakest score in the rating. It signals limited evidence of institutional conviction in the source data.
- Insider Conviction: 9 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and congressional activity does not offer a supportive signal in the source data.
- Macro Regime Fit: 8 / 20. The rating cites Beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive cushion or amplified upside on that basis.
- Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar, indicating a relatively more stable balance sheet than the other pillars suggest.
Taken together, the investor implication is that the rating's upside case rests primarily on balance-sheet resilience and any future cash-generation improvement, while the valuation case is weakened by zero ROIC, zero FCF yield, and the weakest institutional-flow score. Valuation tradeoffs are difficult to quantify because P/E, EV/EBITDA, and EPS are not available in source data.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the catalysts are as follows:
- A Stock Titan item reports a one-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients. This is flagged as MARKET WIRE (YELLOW).
- A Stock Traders Daily item is flagged as RISK WATCH (RED) and carries a risk-zone framing, though its body text provides no quantitative detail.
- Multiple Yahoo Finance and Yahoo! Finance Canada items, a MarketBeat item, and a Google-syndicated item are flagged MARKET WIRE (YELLOW) and largely carry generic "market action" summary language without specific fundamental content.
- A MarketBeat headline references a consensus target price of $20.60 according to brokerages. This is noted here as a news-headline reference only; the analyst section below addresses it further.
The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals. No supply-chain catalyst is therefore available in source data.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, sector correlation data, and 2nd-order bottlenecks are not available in source data. A prospective investor should recognize that the absence of mapped dependencies is itself a gap, not evidence of independence from sector trends.
Open Questions
- What are IMTX's reported revenue, operating income, net income, and free cash flow across recent periods?
- What is the current trailing and forward earnings valuation, given P/E, EPS, and EV/EBITDA are unavailable?
- What specific products or therapies generate the company's business, and who are its customers?
- What is the composition of institutional and insider ownership, and what do recent 13F and Form 4 filings show?
- How does the gynecologic cancer therapy response data relate to the company's regulatory and commercial timeline?
IMTX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Immatics N.V. (IMTX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 14h ago
Immatics N.V. (IMTX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 17h ago
Immatics N.V. (IMTX) stock price, news, quote and history Yahoo Finance UK report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 20h ago
Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to Brokerages MarketBeat report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Traders Daily • 1d ago
Precision Trading with Immatics N.v. (IMTX) Risk Zones Stock Traders Daily report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
One-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients. Stock Titan report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine Media • 1d ago
Can Immatics N.V. (NASDAQ:IMTX) Overcome Its Latest Financial Setback? Kalkine Media report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Immatics (NASDAQ:IMTX) Hits New 1-Year Low - Here's What Happened MarketBeat report covering Immatics N.V. (IMTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 2d ago
Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus What the new PRAME data means for Immatics stock Fresh clinical results for Immatics (NasdaqCM:IMTX) are in focus after updated Phase 1b IMA402 and Phase 1 IMA203CD8 data in PRAME expressing solid tumors were shared at t
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMTX Bull vs. Bear Conversation Board — What's Your Call at $7.20?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMTX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $6.43 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IMTX (D • RQD 45/100) a Buy at $7.31?
Welcome to the IMTX (Immatics N.V.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.70 (-22.0%)
Spot @ $7.31 Pump the brakes on IMTX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IMTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immatics N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.77 (+20.0%)
Spot @ $7.31 IMTX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IMTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.31 (52-wk range $6.65 - $12.41), any beat on forward guidance forces shorts and underweight funds to chase.